SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30

"This collaboration with Castle Biosciences is exciting for SciBase," said Pia Renaudin, CEO of SciBase. "It will accelerate the use of Nevisense within the skin barrier health market. It will rapidly broaden our already existing clinical studies pipeline by increasing the number of studies, ultimately speeding up access to more effective therapies for patients with skin barrier dysfunction. We are also pleased to welcome Castle as a shareholder in SciBase." "This collaboration with Castle...

STOCKHOLM, 17/06/2025 (informazione.news - comunicati stampa - salute e benessere)

 said , CEO of SciBase.

," said , CEO of Castle Biosciences. " ."

In connection with the collaboration and license agreement, SciBase intends to carry out a directed share issue of approximately SEK 30 million . The subscription price in the directed share issue corresponds to SEK 0.40 per share. Castle Biosciences has undertaken to subscribe for 47,886,950 shares in the directed share issue, corresponding to approximately SEK 19 million . Additional information regarding the directed share issue will be announced through a separate press release in connection with this press release and will be available at: https://investors.scibase.se/en/releases

About Skin Barrier Dysfunction

 is a key contributing factor to a wide range of skin disorders - including , and even . Estimates suggest that are affected by conditions in which skin barrier impairment plays a central role.

Additionally, a wide range of -such as dryness, irritation, and product sensitivity-are linked to . These milder forms may affect at some point in their lives.

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

Pia Renaudin , CEO,
Phone. +46732069802
E-mail: pia.renaudin@scibase.com 

DNB Carnegie Investment Bank AB (publ)
Tel: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se

 

 

 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/scibase-has-signed-a-collaboration-and-license-agreement-with-castle-biosciences-to-develop-diagnost,c4164890

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/scibase-has-signed-a-collaboration-and-license-agreement-with-castle-biosciences-to-develop-diagnostic-tests-within-dermatology-and-intends-to-carry-out-a-directed-share-issue-of-approximately-msek-30-302483491.html